Literature DB >> 22157331

Inflammatory bowel disease therapies and cancer risk: where are we and where are we going?

Laurent Beaugerie1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22157331     DOI： 10.1136/gutjnl-2011-301133

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  17 in total

1.  Mucosal schwann cell hamartoma in ulcerative colitis: diagnosis and clinical relevance.

Authors:  Welmoed K van Deen; Daniel W Hommes
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-03

2.  A population-based study examining the risk of malignancy in patients diagnosed with inflammatory bowel disease.

Authors:  J Claire Wilson; Raoul I Furlano; Susan S Jick; Christoph R Meier
Journal:  J Gastroenterol       Date:  2016-04-07       Impact factor: 7.527

3.  The benefit-to-risk balance of combining infliximab with azathioprine varies with age: a markov model.

Authors:  Frank I Scott; Ravy K Vajravelu; Meenakshi Bewtra; Ronac Mamtani; Dale Lee; David S Goldberg; James D Lewis
Journal:  Clin Gastroenterol Hepatol       Date:  2014-08-10       Impact factor: 11.382

4.  Increased expression and possible role of chitinase 3-like-1 in a colitis-associated carcinoma model.

Authors:  Jia-Yi Ma; Run-Hua Li; Kun Huang; Gao Tan; Chen Li; Fa-Chao Zhi
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

Review 5.  Understanding the Cautions and Contraindications of Immunomodulator and Biologic Therapies for Use in Inflammatory Bowel Disease.

Authors:  H Matthew Cohn; Maneesh Dave; Edward V Loftus
Journal:  Inflamm Bowel Dis       Date:  2017-08       Impact factor: 5.325

Review 6.  Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment.

Authors:  Jordan E Axelrad; Simon Lichtiger; Vijay Yajnik
Journal:  World J Gastroenterol       Date:  2016-05-28       Impact factor: 5.742

7.  AHR Activation Is Protective against Colitis Driven by T Cells in Humanized Mice.

Authors:  Jeremy A Goettel; Roopali Gandhi; Jessica E Kenison; Ada Yeste; Gopal Murugaiyan; Sharmila Sambanthamoorthy; Alexandra E Griffith; Bonny Patel; Dror S Shouval; Howard L Weiner; Scott B Snapper; Francisco J Quintana
Journal:  Cell Rep       Date:  2016-10-25       Impact factor: 9.423

Review 8.  Risk of Cancer in Inflammatory Bowel Disease and Pitfalls in Oncologic Therapy.

Authors:  Renata D Peixoto; Artur R Ferreira; James M Cleary; João P Fogacci; João P Vasconcelos; Alexandre A Jácome
Journal:  J Gastrointest Cancer       Date:  2022-03-14

Review 9.  Use of Methotrexate in the Treatment of Inflammatory Bowel Diseases.

Authors:  Hans H Herfarth; Michael D Kappelman; Millie D Long; Kim L Isaacs
Journal:  Inflamm Bowel Dis       Date:  2016-01       Impact factor: 5.325

Review 10.  Use of biologics and chemotherapy in patients with inflammatory bowel diseases and cancer.

Authors:  Aranzazu Jauregui-Amezaga; Séverine Vermeire; Hans Prenen
Journal:  Ann Gastroenterol       Date:  2016 Apr-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.